SCHEMBL3550108

SCHEMBL3550108

OC(=S)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.56
GAA P10253 1/20 0.48
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
P2RX1 P51575 2/20 0.40
CTSL P07711 2/20 0.40
CTSB P07858 2/20 0.40
MAPT P10636 2/20 0.39
TACR1 P25103 2/20 0.39
MYC P01106 1/20 0.39
MAX P61244 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549813 0.80 RXRA (0.44) CES2GAARXRARXRBRXRG
SCHEMBL14471508 0.79 CES2 (0.61) CES2GAARXRARXRBRXRG
SCHEMBL627496 0.78 GAA (0.56) CES2GAARXRARXRBRXRG
SCHEMBL20560191 0.78 CES2 (0.54) CES2GAARXRARXRBRXRG
SCHEMBL3554040 0.78 CES2 (0.62) CES2GAAP2RX1MAPT
SCHEMBL13984577 0.77 CES2 (0.58) CES2GAARXRARXRBRXRG
Hydrochloric Acid SCHEMBL11545126 0.76 CES2 (0.60) CES2GAAP2RX1MAPT
SCHEMBL4089228 0.76 CES2 (0.64) CES2GAARXRARXRBRXRG
SCHEMBL503980 0.75 CES2 (0.70) CES2GAARXRARXRBRXRG
SCHEMBL3020722 0.75 GABRA1 (0.50) GAARXRARXRBRXRGMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE CES2 625/4885GAA 19/4885RXRA 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.